{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(11)"],"submitter":["Ruan K"],"pubmed_abstract":["This prospective observational study investigated the efficacy of pembrolizumab administered as first-line therapy and the survival outcomes of continuing or combining it with other agents after disease progression in patients with stage IV non-small cell lung cancer (NSCLC). A total of 63 patients who experienced disease progression following pembrolizumab-based first-line treatment between February 2019 and July 2024 were prospectively enrolled. Patients were randomized into two cohorts based on treatment strategy: a treated beyond progression (TBP) group (n = 39) to receive continued pembrolizumab monotherapy or pembrolizumab-based combination regimens after disease progression, and a non-TBP (NTBP) group (n = 24), which discontinued pembrolizumab upon progression. The primary endpoint "],"journal":["American journal of cancer research"],"pagination":["4934-4944"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12696522"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy of continuing pembrolizumab after progression on first-line treatment in stage IV non-small cell lung cancer: a prospective real-world study."],"pmcid":["PMC12696522"],"pubmed_authors":["Chen P","Shao J","Wang B","Lv X","Qu J","Han Z","Wu D","Ruan K","Zheng J","Ding Y","Huang W","Sun D","Tang Y","Wu X","Xu Y","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of continuing pembrolizumab after progression on first-line treatment in stage IV non-small cell lung cancer: a prospective real-world study.","description":"This prospective observational study investigated the efficacy of pembrolizumab administered as first-line therapy and the survival outcomes of continuing or combining it with other agents after disease progression in patients with stage IV non-small cell lung cancer (NSCLC). A total of 63 patients who experienced disease progression following pembrolizumab-based first-line treatment between February 2019 and July 2024 were prospectively enrolled. Patients were randomized into two cohorts based on treatment strategy: a treated beyond progression (TBP) group (n = 39) to receive continued pembrolizumab monotherapy or pembrolizumab-based combination regimens after disease progression, and a non-TBP (NTBP) group (n = 24), which discontinued pembrolizumab upon progression. The primary endpoint ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-06T03:55:25.388Z","creation":"2026-05-25T03:12:00.785Z"},"accession":"S-EPMC12696522","cross_references":{"pubmed":["41395281"],"doi":["10.62347/GFTO6440","10.62347/gfto6440"]}}